UnknownNot Applicable

Continuous Ambulatory ECG Monitoring for Detection of Postoperative Atrial Fibrillation Following Thoracic Surgery

Canada100 participantsStarted 2020-04-01

Plain-language summary

Atrial fibrillation (AF) is a common and serious complication after lung resection. The incidence is likely underestimated, and risk may persist after leaving hospital. Recent development of simple wearable patch ECG devices may provide sensitive detection of AF in the extended postoperative period. Specific biomarkers may allow us to predict which patients are at risk of developing postoperative AF.

Who can participate

Age range55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patients, age ≥ 55 years at time of surgery, undergoing thoracic surgery with general anesthesia
✓. Co-enrolment in the NT-proBNP biomarker monitoring study

Exclusion criteria

✕. Patients with a prior history of documented AF
✕. Patients with an implanted pacemaker or defibrillator
✕. Patients currently taking anti-arrhythmic medication other than ß- blockers, calcium channel blockers or digoxin
✕. Patients undergoing minor thoracic interventions/procedures (i.e., minor chest-wall surgeries, chest tube insertions, or needle pleural/lung biopsies)
✕. Patients who are unable or unwilling to wear the CardioSTAT device as per manufacturer's guidelines, or who are unable/unwilling to return the device via mail to Icentia for procession and analysis
✕. Patients with known allergy to adhesives

What they're measuring

Absolute incidence of postoperative atrial fibrillation

Timeframe: 14 days postop

Trial details

NCT IDNCT04325269

SponsorUniversity of Manitoba

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-02-01

Contact for this trial

Sadeesh Srinathan, MD

2047873791 ssrinathan@hsc.mb.ca

View on ClinicalTrials.gov More Lung Cancer trials